The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.
This study will test whether administration of anakinra, an IL-1 receptor antagonist, will decrease pain and improve wound healing in patients undergoing vascular or orthopedic surgical procedures. The investigators will administer two doses of Anakinra via an injection under the skin, one dose one hour before surgery and a second dose on the first postoperative day (24 hours after surgery). The investigators will remove fluid from the surgical incisions using a small plastic catheter placed under skin during surgery and measure the amounts of pain- causing inflammatory mediators. The investigators will also measure the amount of pain the participant is experiencing using questions about pain intensity and by gently touching the incision to determine sensitivity of the incision site.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
13
An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
Stanford Hospital and Clinics
Stanford, California, United States
Concentration Levels of Inflammatory Mediators IL-1 Receptor Antagonist (IL-1ra) Present in Human Wounds Following Surgery With and Without the Use of Anakinra.
Tissue samples were collected at the surgical wound site at 3 time points during the 1st 72 hours following surgery. Tissue samples from subjects receiving placebo, and subjects receiving anakinra injections pre, and post op were analyzed for IL-1
Time frame: Up to 72 hours following surgery
Number of Participants With Analgesic Consumption During the 72 Hours Following Surgery
Analgesic consumption is reported as the count of participants receiving each analgesic type. Comparisons between the placebo and active drug groups were made at the conclusion of the study. PCA/IV: Patient controlled Analgesia/ Intravenous
Time frame: Up to 72 hours following surgery
Post-operative Pain Intensity
Pain was measured on Day 1 and day 2 following surgery using a VAS scale at rest and on stimulation with Visual Analog Scale (VAS) of 1-10 (1=no pain and 10=worst pain)
Time frame: Up to 72 hours following surgery
Count of Participants Experiencing Wound Infection in the Study From Surgery Till the Time of Discharge From the Hospital
Evaluation of the surgical wound for symptoms of wound infection was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of wound infection.
Time frame: Up to 72 hours following surgery plus 3 weeks follow-up
Count of Participants With Venous Thrombosis After Surgery During Hospitalization
Evaluation of the surgical wound for symptoms of venous thrombosis was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of venous thrombosis.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 72 hours following surgery plus 3 weeks follow-up
Assess Rates of Wound Dehiscence
Evaluation of the surgical wound for symptoms of wound dehiscence was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of wound dehiscence.
Time frame: Up to 72 hours following surgery plus 3 weeks follow-up
Total Length of Hospital Stay
Total length of hospital stay for patients enrolled in the study.
Time frame: Up to approximately 5 days maximum (admittance to discharge)